Patients with high-risk MPN, CMML, or AML had a median OS of 13.3 months, while MPN and CMML patients with an extended duration of PARP inhibition had an ORR of 67% and an OS of 15.8 months, without significant adverse events [92]. Here, PARP1 is linked to myeloproliferative neoplasm.